The Role of STAT Signaling Pathways in the Pathogenesis of Systemic Lupus Erythematosus

Clinical Reviews in Allergy and Immunology

Volumn 52, Issue 2, 2017, Pages 164-181

  Goropevšek, Aleš ^a,b   Holcar, Marija ^c   Avčin, Tadej ^c,d  

^a UNIVERSITY MEDICAL CENTRE MARIBOR   (Slovenia)

^b UNIVERSITY OF MARIBOR   (Slovenia)

^c UNIVERSITY MEDICAL CENTRE LJUBLJANA   (Slovenia)

^d UNIVERSITY OF LJUBLJANA   (Slovenia)

Author keywords

JAK STAT signaling pathway; Pathogenesis of systemic lupus erythematosus

Indexed keywords

INTERFERON; INTERLEUKIN 10; JANUS KINASE; STAT PROTEIN; STAT1 PROTEIN; STAT2 PROTEIN; STAT3 PROTEIN; STAT4 PROTEIN; STAT5 PROTEIN; STAT5A PROTEIN; STAT5B PROTEIN; STAT6 PROTEIN;

B LYMPHOCYTE; CD4+ T LYMPHOCYTE; DISEASE PREDISPOSITION; EPIGENETICS; GENOME-WIDE ASSOCIATION STUDY; HELPER CELL; HUMAN; LYMPHOCYTE DIFFERENTIATION; NONHUMAN; PATHOGENESIS; REVIEW; SIGNAL TRANSDUCTION; STAT4 GENE; SYSTEMIC LUPUS ERYTHEMATOSUS; TH17 CELL; METABOLISM; PATHOPHYSIOLOGY; PHYSIOLOGY;

HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; SIGNAL TRANSDUCTION; STAT TRANSCRIPTION FACTORS;

EID: 84969821674     PISSN: 10800549     EISSN: 15590267     Source Type: Journal    
DOI: 10.1007/s12016-016-8550-y     Document Type: Review

References (187)

1. Altshuler D, Daly MJ, Lander ES (2008) Genetic mapping in human disease. Science 322:881–888
2. Parkes M, Cortes A, van Heel DA, Brown MA (2013) Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 14:661–673
3. Ghodke-Puranik Y, Niewold TB (2015) Immunogenetics of systemic lupus erythematosus: a comprehensive review. J Autoimmun 64:125–136
4. Rullo OJ, Tsao BP (2013) Recent insights into the genetic basis of systemic lupus erythematosus. Ann Rheum Dis 72(Suppl 2):ii56–ii61
5. Tak YG, Farnham PJ (2015) Making sense of GWAS: using epigenomics and genome engineering to understand the functional relevance of SNPs in non-coding regions of the human genome. Epigenetics Chromatin 8:57
6. Farh KK, Marson A, Zhu J et al (2015) Genetic and epigenetic fine mapping of causal autoimmune disease variants. Nature 518:337–343
7. Maurano MT, Humbert R, Rynes E et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. Science 337:1190–1195
8. Miguel-Escalada I, Pasquali L, Ferrer J (2015) Transcriptional enhancers: functional insights and role in human disease. Curr Opin Genet Dev 33:71–76
9. Hnisz D, Abraham BJ, Lee TI et al (2013) Super-enhancers in the control of cell identity and disease. Cell 155:934–947
10. Parker SC, Stitzel ML, Taylor DL et al (2013) Chromatin stretch enhancer states drive cell-specific gene regulation and harbor human disease risk variants. Proc Natl Acad Sci U S A 110:17921–17926
11. Vahedi G, Kanno Y, Furumoto Y et al (2015) Super-enhancers delineate disease-associated regulatory nodes in T cells. Nature 520:558–562
12. Vahedi G, Takahashi H, Nakayamada S et al (2012) STATs shape the active enhancer landscape of T cell populations. Cell 151:981–993
13. Stark GR, Darnell JE Jr (2012) The JAK-STAT pathway at twenty. Immunity 36:503–514
14. Levy DE, Darnell JE Jr (2002) Stats: transcriptional control and biological impact. Nat Rev Mol Cell Biol 3:651–662
15. Li HS, Watowich SS (2014) Innate immune regulation by STAT-mediated transcriptional mechanisms. Immunol Rev 261:84–101
16. Villarino AV, Kanno Y, Ferdinand JR, O'Shea JJ (2015) Mechanisms of Jak/STAT signaling in immunity and disease. J Immunol 194:21–27
17. Bohmer FD, Friedrich K (2014) Protein tyrosine phosphatases as wardens of STAT signaling. Jakstat 3, e28087
18. Darnell JE Jr, Kerr IM, Stark GR (1994) Jak-STAT pathways and transcriptional activation in response to IFNs and other extracellular signaling proteins. Science 264:1415–1421
19. Darnell JE Jr (1997) STATs and gene regulation. Science 277:1630–1635
20. Liongue C, Ward AC (2013) Evolution of the JAK-STAT pathway. Jakstat 2, e22756
21. Decker T, Kovarik P (2000) Serine phosphorylation of STATs. Oncogene 19:2628–2637
22. Dorritie KA, Redner RL, Johnson DE (2014) STAT transcription factors in normal and cancer stem cells. Adv Biol Regul 56:30–44
23. Ehret GB, Reichenbach P, Schindler U et al (2001) DNA binding specificity of different STAT proteins. Comparison of in vitro specificity with natural target sites. J Biol Chem 276:6675–6688
24. Au-Yeung N, Mandhana R, Horvath CM (2013) Transcriptional regulation by STAT1 and STAT2 in the interferon JAK-STAT pathway. Jakstat 2, e23931
25. Abroun S, Saki N, Ahmadvand M, Asghari F, Salari F, Rahim F (2015) STATs: an old story, yet mesmerizing. Cell J 17:395–411
26. Vinkemeier U, Cohen SL, Moarefi I, Chait BT, Kuriyan J, Darnell JE Jr (1996) DNA binding of in vitro activated Stat1 alpha, Stat1 beta and truncated Stat1: interaction between NH2-terminal domains stabilizes binding of two dimers to tandem DNA sites. EMBO J 15:5616–5626
27. Reich NC (2013) STATs get their move on. Jakstat 2, e27080
28. Saleiro D, Platanias LC (2015) Intersection of mTOR and STAT signaling in immunity. Trends Immunol 36:21–29
29. Woo CH, Shishido T, McClain C et al (2008) Extracellular signal-regulated kinase 5 SUMOylation antagonizes shear stress-induced antiinflammatory response and endothelial nitric oxide synthase expression in endothelial cells. Circ Res 102:538–545
30. Yang J, Stark GR (2008) Roles of unphosphorylated STATs in signaling. Cell Res 18:443–451
31. O'Shea JJ, Notarangelo LD, Johnston JA, Candotti F (1997) Advances in the understanding of cytokine signal transduction: the role of Jaks and STATs in immunoregulation and the pathogenesis of immunodeficiency. J Clin Immunol 17:431–447
32. Zhong M, Henriksen MA, Takeuchi K et al (2005) Implications of an antiparallel dimeric structure of nonphosphorylated STAT1 for the activation-inactivation cycle. Proc Natl Acad Sci U S A 102:3966–3971
33. Wenta N, Strauss H, Meyer S, Vinkemeier U (2008) Tyrosine phosphorylation regulates the partitioning of STAT1 between different dimer conformations. Proc Natl Acad Sci U S A 105:9238–9243
34. Porritt RA, Hertzog PJ (2015) Dynamic control of type I IFN signalling by an integrated network of negative regulators. Trends Immunol 36:150–160
35. Lui PY, Jin DY, Stevenson NJ (2015) MicroRNA: master controllers of intracellular signaling pathways. Cell Mol Life Sci 72:3531–3542
36. Witte S, Muljo SA (2014) Integrating non-coding RNAs in JAK-STAT regulatory networks. Jakstat 3, e28055
37. Bocchini CE, Kasembeli MM, Roh SH, Tweardy DJ (2014) Contribution of chaperones to STAT pathway signaling. Jakstat 3, e970459
38. Schindler CW (2002) Series introduction. JAK-STAT signaling in human disease. J Clin Invest 109:1133–1137
39. Ward AC, Touw I, Yoshimura A (2000) The Jak-Stat pathway in normal and perturbed hematopoiesis. Blood 95:19–29
40. O'Shea JJ, Schwartz DM, Villarino AV, Gadina M, McInnes IB, Laurence A (2015) The JAK-STAT pathway: impact on human disease and therapeutic intervention. Annu Rev Med 66:311–328
41. Holcar M, Goropevsek A, Ihan A, Avcin T (2015) Age-related differences in percentages of regulatory and effector T lymphocytes and their subsets in healthy individuals and characteristic STAT1/STAT5 signalling response in helper T lymphocytes. J Immunol Res 2015:352934
42. Li G, Ju J, Weyand CM, Goronzy JJ (2015) Age-associated failure to adjust type I IFN receptor signaling thresholds after T cell activation. J Immunol 195:865–874
43. Raphael I, Nalawade S, Eagar TN, Forsthuber TG (2015) T cell subsets and their signature cytokines in autoimmune and inflammatory diseases. Cytokine 74:5–17
44. Zhu J, Paul WE (2010) Peripheral CD4+ T-cell differentiation regulated by networks of cytokines and transcription factors. Immunol Rev 238:247–262
45. Bonelli M, Shih HY, Hirahara K et al (2014) Helper T cell plasticity: impact of extrinsic and intrinsic signals on transcriptomes and epigenomes. Curr Top Microbiol Immunol 381:279–326
46. Tripathi SK, Lahesmaa R (2014) Transcriptional and epigenetic regulation of T-helper lineage specification. Immunol Rev 261:62–83
47. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O'Garra A, Murphy KM (1993) Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260:547–549
48. Girdlestone J, Wing M (1996) Autocrine activation by interferon-gamma of STAT factors following T cell activation. Eur J Immunol 26:704–709
49. Szabo SJ, Kim ST, Costa GL, Zhang X, Fathman CG, Glimcher LH (2000) A novel transcription factor, T-bet, directs Th1 lineage commitment. Cell 100:655–669
50. Sokol CL, Barton GM, Farr AG, Medzhitov R (2008) A mechanism for the initiation of allergen-induced T helper type 2 responses. Nat Immunol 9:310–318
51. Zheng W, Flavell RA (1997) The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 89:587–596
52. Park H, Li Z, Yang XO et al (2005) A distinct lineage of CD4 T cells regulates tissue inflammation by producing interleukin 17. Nat Immunol 6:1133–1141
53. Ivanov II, McKenzie BS, Zhou L et al (2006) The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells. Cell 126:1121–1133
54. Veldhoen M, Uyttenhove C, van Snick J et al (2008) Transforming growth factor-beta ‘reprograms’ the differentiation of T helper 2 cells and promotes an interleukin 9-producing subset. Nat Immunol 9:1341–1346
55. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H (2009) Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 10:864–871
56. Ma CS, Deenick EK (2014) Human T follicular helper (Tfh) cells and disease. Immunol Cell Biol 92:64–71
57. Ma CS, Avery DT, Chan A et al (2012) Functional STAT3 deficiency compromises the generation of human T follicular helper cells. Blood 119:3997–4008
58. Toda A, Piccirillo CA (2006) Development and function of naturally occurring CD4+CD25+ regulatory T cells. J Leukoc Biol 80:458–470
59. Chen W, Jin W, Hardegen N et al (2003) Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 198:1875–1886
60. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA (2007) IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 178:2018–2027
61. Mahmud SA, Manlove LS, Farrar MA (2013) Interleukin-2 and STAT5 in regulatory T cell development and function. Jakstat 2, e23154
62. Duhen R, Glatigny S, Arbelaez CA, Blair TC, Oukka M, Bettelli E (2013) Cutting edge: the pathogenicity of IFN-gamma-producing Th17 cells is independent of T-bet. J Immunol 190:4478–4482
63. Lochner M, Peduto L, Cherrier M et al (2008) In vivo equilibrium of proinflammatory IL-17+ and regulatory IL-10+ Foxp3+ RORgamma t+ T cells. J Exp Med 205:1381–1393
64. Zhou X, Bailey-Bucktrout SL, Jeker LT et al (2009) Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo. Nat Immunol 10:1000–1007
65. Nguyen ML, Jones SA, Prier JE, Russ BE (2015) Transcriptional enhancers in the regulation of T cell differentiation. Front Immunol 6:462
66. Witte S, O'Shea JJ, Vahedi G (2015) Super-enhancers: asset management in immune cell genomes. Trends Immunol 36:519–526
67. O'Shea JJ, Lahesmaa R, Vahedi G, Laurence A, Kanno Y (2011) Genomic views of STAT function in CD4+ T helper cell differentiation. Nat Rev Immunol 11:239–250
68. Ciofani M, Madar A, Galan C et al (2012) A validated regulatory network for Th17 cell specification. Cell 151:289–303
69. O'Shea JJ, Murray PJ (2008) Cytokine signaling modules in inflammatory responses. Immunity 28:477–487
70. Leonard WJ (2001) Cytokines and immunodeficiency diseases. Nat Rev Immunol 1:200–208
71. Murray PJ (2007) The JAK-STAT signaling pathway: input and output integration. J Immunol 178:2623–2629
72. Avery DT, Deenick EK, Ma CS et al (2010) B cell-intrinsic signaling through IL-21 receptor and STAT3 is required for establishing long-lived antibody responses in humans. J Exp Med 207:155–171
73. Deenick EK, Avery DT, Chan A et al (2013) Naive and memory human B cells have distinct requirements for STAT3 activation to differentiate into antibody-secreting plasma cells. J Exp Med 210:2739–2753
74. Miklossy G, Hilliard TS, Turkson J (2013) Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov 12:611–629
75. Adamkova L, Souckova K, Kovarik J (2007) Transcription protein STAT1: biology and relation to cancer. Folia Biol (Praha) 53:1–6
76. Szabo SJ, Sullivan BM, Peng SL, Glimcher LH (2003) Molecular mechanisms regulating Th1 immune responses. Annu Rev Immunol 21:713–758
77. Liu L, Okada S, Kong XF et al (2011) Gain-of-function human STAT1 mutations impair IL-17 immunity and underlie chronic mucocutaneous candidiasis. J Exp Med 208:1635–1648
78. van de Veerdonk FL, Plantinga TS, Hoischen A et al (2011) STAT1 mutations in autosomal dominant chronic mucocutaneous candidiasis. N Engl J Med 365:54–61
79. Uzel G, Sampaio EP, Lawrence MG et al (2013) Dominant gain-of-function STAT1 mutations in FOXP3 wild-type immune dysregulation-polyendocrinopathy-enteropathy-X-linked-like syndrome. J Allergy Clin Immunol 131:1611–1623
80. Hadj-Slimane R, Chelbi-Alix MK, Tovey MG, Bobe P (2004) An essential role for IFN-alpha in the overexpression of Fas ligand on MRL/lpr lymphocytes and on their spontaneous Fas-mediated cytotoxic potential. J Interferon Cytokine Res 24:717–728
81. Dong J, Wang QX, Zhou CY, Ma XF, Zhang YC (2007) Activation of the STAT1 signalling pathway in lupus nephritis in MRL/lpr mice. Lupus 16:101–109
82. Hale MB, Krutzik PO, Samra SS, Crane JM, Nolan GP (2009) Stage dependent aberrant regulation of cytokine-STAT signaling in murine systemic lupus erythematosus. PLoS One 4, e6756
83. Reeves WH, Lee PY, Weinstein JS, Satoh M, Lu L (2009) Induction of autoimmunity by pristane and other naturally occurring hydrocarbons. Trends Immunol 30:455–464
84. Thibault DL, Chu AD, Graham KL et al (2008) IRF9 and STAT1 are required for IgG autoantibody production and B cell expression of TLR7 in mice. J Clin Invest 118:1417–1426
85. Yiu G, Rasmussen TK, Ajami B et al (2015) Development of Th17-associated interstitial kidney inflammation in lupus-prone mice lacking the gene encoding STAT-1. Arthritis Rheumatol
86. Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK (2014) Positive correlation of STAT1 and miR-146a with anemia in patients with systemic lupus erythematosus. J Clin Immunol 34:171–180
87. Dominguez-Gutierrez PR, Ceribelli A, Satoh M, Sobel ES, Reeves WH, Chan EK (2014) Elevated signal transducers and activators of transcription 1 correlates with increased C-C motif chemokine ligand 2 and C-X-C motif chemokine 10 levels in peripheral blood of patients with systemic lupus erythematosus. Arthritis Res Ther 16:R20
88. Lu MC, Lai NS, Chen HC et al (2013) Decreased microRNA(miR)-145 and increased miR-224 expression in T cells from patients with systemic lupus erythematosus involved in lupus immunopathogenesis. Clin Exp Immunol 171:91–99
89. Karonitsch T, Feierl E, Steiner CW et al (2009) Activation of the interferon-gamma signaling pathway in systemic lupus erythematosus peripheral blood mononuclear cells. Arthritis Rheum 60:1463–1471
90. Menon M, Blair PA, Isenberg DA, Mauri C (2016) A regulatory feedback between plasmacytoid dendritic cells and regulatory B cells is aberrant in systemic lupus erythematosus. Immunity 44:683–697
91. Huang X, Guo Y, Bao C, Shen N (2011) Multidimensional single cell based STAT phosphorylation profiling identifies a novel biosignature for evaluation of systemic lupus erythematosus activity. PLoS One 6, e21671
92. Ivashkiv LB, Donlin LT (2014) Regulation of type I interferon responses. Nat Rev Immunol 14:36–49
93. Baechler EC, Batliwalla FM, Karypis G et al (2003) Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci U S A 100:2610–2615
94. Liang Y, Xu WD, Yang XK et al (2014) Association of signaling transducers and activators of transcription 1 and systemic lupus erythematosus. Autoimmunity 47:141–145
95. Zhuang H, Szeto C, Han S, Yang L, Reeves WH (2015) Animal models of interferon signature positive lupus. Front Immunol 6:291
96. Landolt-Marticorena C, Bonventi G, Lubovich A et al (2009) Lack of association between the interferon-alpha signature and longitudinal changes in disease activity in systemic lupus erythematosus. Ann Rheum Dis 68:1440–1446
97. Petri M, Singh S, Tesfasyone H et al (2009) Longitudinal expression of type I interferon responsive genes in systemic lupus erythematosus. Lupus 18:980–989
98. Gamero AM, Young MR, Mentor-Marcel R et al (2010) STAT2 contributes to promotion of colorectal and skin carcinogenesis. Cancer Prev Res (Phila) 3:495–504
99. Matsumoto M, Tanaka N, Harada H et al (1999) Activation of the transcription factor ISGF3 by interferon-gamma. Biol Chem 380:699–703
100. Abdul-Sater AA, Majoros A, Plumlee CR et al (2015) Different STAT transcription complexes drive early and delayed responses to type I IFNs. J Immunol 195:210–216
101. Hambleton S, Goodbourn S, Young DF et al (2013) STAT2 deficiency and susceptibility to viral illness in humans. Proc Natl Acad Sci U S A 110:3053–3058
102. Sriram U, Varghese L, Bennett HL et al (2012) Myeloid dendritic cells from B6.NZM Sle1/Sle2/Sle3 lupus-prone mice express an IFN signature that precedes disease onset. J Immunol 189:80–91
103. Ramirez-Velez G, Medina F, Ramirez-Montano L et al (2012) Constitutive phosphorylation of interferon receptor A-associated signaling proteins in systemic lupus erythematosus. PLoS One 7, e41414
104. Baccala R, Gonzalez-Quintial R, Schreiber RD, Lawson BR, Kono DH, Theofilopoulos AN (2012) Anti-IFN-α/β receptor antibody treatment ameliorates disease in lupus-predisposed mice. J Immunol 189:5976–5984
105. Munroe ME, Lu R, Zhao YD et al (2016) Altered type II interferon precedes autoantibody accrual and elevated type I interferon activity prior to systemic lupus erythematosus classification. Ann Rheum Dis. doi:10.1136/annrheumdis-2015-208140
106. Yang XO, Panopoulos AD, Nurieva R et al (2007) STAT3 regulates cytokine-mediated generation of inflammatory helper T cells. J Biol Chem 282:9358–9363
107. Durant L, Watford WT, Ramos HL et al (2010) Diverse targets of the transcription factor STAT3 contribute to T cell pathogenicity and homeostasis. Immunity 32:605–615
108. Harris TJ, Grosso JF, Yen HR et al (2007) Cutting edge: an in vivo requirement for STAT3 signaling in TH17 development and TH17-dependent autoimmunity. J Immunol 179:4313–4317
109. Liu X, Lee YS, Yu CR, Egwuagu CE (2008) Loss of STAT3 in CD4+ T cells prevents development of experimental autoimmune diseases. J Immunol 180:6070–6076
110. Zhu Y, Zou L, Liu YC (2016) T follicular helper cells, T follicular regulatory cells and autoimmunity. Int Immunol 28:173–179
111. Moens L, Tangye SG (2014) Cytokine-Mediated regulation of plasma cell generation: IL-21 takes center stage. Front Immunol 5:65
112. Liu K, Liang C, Liang Z, Tus K, Wakeland EK (2005) Sle1ab mediates the aberrant activation of STAT3 and Ras-ERK signaling pathways in B lymphocytes. J Immunol 174:1630–1637
113. Nakou M, Bertsias G, Stagakis I et al (2010) Gene network analysis of bone marrow mononuclear cells reveals activation of multiple kinase pathways in human systemic lupus erythematosus. PLoS One 5, e13351
114. Harada T, Kyttaris V, Li Y, Juang YT, Wang Y, Tsokos GC (2007) Increased expression of STAT3 in SLE T cells contributes to enhanced chemokine-mediated cell migration. Autoimmunity 40:1–8
115. Edwards LJ, Mizui M, Kyttaris V (2015) Signal transducer and activator of transcription (STAT) 3 inhibition delays the onset of lupus nephritis in MRL/lpr mice. Clin Immunol 158:221–230
116. Balomenos D, Rumold R, Theofilopoulos AN (1998) Interferon-gamma is required for lupus-like disease and lymphoaccumulation in MRL-lpr mice. J Clin Invest 101:364–371
117. Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley VR (1998) IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas(lpr) mice. J Immunol 161:494–503
118. Haas C, Ryffel B, Le Hir M (1998) IFN-gamma receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW)F1 mice. J Immunol 160:3713–3718
119. Ferber IA, Brocke S, Taylor-Edwards C et al (1996) Mice with a disrupted IFN-gamma gene are susceptible to the induction of experimental autoimmune encephalomyelitis (EAE). J Immunol 156:5–7
120. Willenborg DO, Fordham S, Bernard CC, Cowden WB, Ramshaw IA (1996) IFN-gamma plays a critical down-regulatory role in the induction and effector phase of myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. J Immunol 157:3223–3227
121. Chitnis T, Najafian N, Benou C et al (2001) Effect of targeted disruption of STAT4 and STAT6 on the induction of experimental autoimmune encephalomyelitis. J Clin Invest 108:739–747
122. Singh RR, Saxena V, Zang S et al (2003) Differential contribution of IL-4 and STAT6 vs STAT4 to the development of lupus nephritis. J Immunol 170:4818–4825
123. Jacob CO, Zang S, Li L et al (2003) Pivotal role of Stat4 and Stat6 in the pathogenesis of the lupus-like disease in the New Zealand mixed 2328 mice. J Immunol 171:1564–1571
124. Menke J, Bork T, Kutska B et al (2011) Targeting transcription factor Stat4 uncovers a role for interleukin-18 in the pathogenesis of severe lupus nephritis in mice. Kidney Int 79:452–463
125. Remmers EF, Plenge RM, Lee AT et al (2007) STAT4 and the risk of rheumatoid arthritis and systemic lupus erythematosus. N Engl J Med 357:977–986
126. Han JW, Zheng HF, Cui Y et al (2009) Genome-wide association study in a Chinese Han population identifies nine new susceptibility loci for systemic lupus erythematosus. Nat Genet 41:1234–1237
127. Graham RR, Cotsapas C, Davies L et al (2008) Genetic variants near TNFAIP3 on 6q23 are associated with systemic lupus erythematosus. Nat Genet 40:1059–1061
128. Harley JB, Alarcon-Riquelme ME, Criswell LA et al (2008) Genome-wide association scan in women with systemic lupus erythematosus identifies susceptibility variants in ITGAM, PXK, KIAA1542 and other loci. Nat Genet 40:204–210
129. Gateva V, Sandling JK, Hom G et al (2009) A large-scale replication study identifies TNIP1, PRDM1, JAZF1, UHRF1BP1 and IL10 as risk loci for systemic lupus erythematosus. Nat Genet 41:1228–1233
130. Bolin K, Sandling JK, Zickert A et al (2013) Association of STAT4 polymorphism with severe renal insufficiency in lupus nephritis. PLoS One 8, e84450
131. Svenungsson E, Gustafsson J, Leonard D et al (2010) A STAT4 risk allele is associated with ischaemic cerebrovascular events and anti-phospholipid antibodies in systemic lupus erythematosus. Ann Rheum Dis 69:834–840
132. Korman BD, Kastner DL, Gregersen PK, Remmers EF (2008) STAT4: genetics, mechanisms, and implications for autoimmunity. Curr Allergy Asthma Rep 8:398–403
133. Namjou B, Sestak AL, Armstrong DL et al (2009) High-density genotyping of STAT4 reveals multiple haplotypic associations with systemic lupus erythematosus in different racial groups. Arthritis Rheum 60:1085–1095
134. Lamana A, Lopez-Santalla M, Castillo-Gonzalez R et al (2015) The minor allele of rs7574865 in the STAT4 gene is associated with increased mRNA and protein expression. PLoS One 10, e0142683
135. Cho SS, Bacon CM, Sudarshan C et al (1996) Activation of STAT4 by IL-12 and IFN-alpha: evidence for the involvement of ligand-induced tyrosine and serine phosphorylation. J Immunol 157:4781–4789
136. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB (2009) Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 182:34–38
137. Hellquist A, Jarvinen TM, Koskenmies S et al (2009) Evidence for genetic association and interaction between the TYK2 and IRF5 genes in systemic lupus erythematosus. J Rheumatol 36:1631–1638
138. Connolly JJ, Hakonarson H (2012) Role of cytokines in systemic lupus erythematosus: recent progress from GWAS and sequencing. J Biomed Biotechnol 2012:798924
139. Sigurdsson S, Nordmark G, Garnier S et al (2008) A risk haplotype of STAT4 for systemic lupus erythematosus is over-expressed, correlates with anti-dsDNA and shows additive effects with two risk alleles of IRF5. Hum Mol Genet 17:2868–2876
140. Abelson AK, Delgado-Vega AM, Kozyrev SV et al (2009) STAT4 associates with systemic lupus erythematosus through two independent effects that correlate with gene expression and act additively with IRF5 to increase risk. Ann Rheum Dis 68:1746–1753
141. Lin JX, Leonard WJ (2000) The role of Stat5a and Stat5b in signaling by IL-2 family cytokines. Oncogene 19:2566–2576
142. Akira S (1999) Functional roles of STAT family proteins: lessons from knockout mice. Stem Cells 17:138–146
143. Antov A, Yang L, Vig M, Baltimore D, Van Parijs L (2003) Essential role for STAT5 signaling in CD25+CD4+ regulatory T cell homeostasis and the maintenance of self-tolerance. J Immunol 171:3435–3441
144. Cohen AC, Nadeau KC, Tu W et al (2006) Cutting edge: decreased accumulation and regulatory function of CD4+ CD25(high) T cells in human STAT5b deficiency. J Immunol 177:2770–2774
145. Piccirillo CA, d'Hennezel E, Sgouroudis E, Yurchenko E (2008) CD4+Foxp3+ regulatory T cells in the control of autoimmunity: in vivo veritas. Curr Opin Immunol 20:655–662
146. Jenks JA, Seki S, Kanai T et al (2013) Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. Clin Immunol 148:227–236
147. Yang XP, Ghoreschi K, Steward-Tharp SM et al (2011) Opposing regulation of the locus encoding IL-17 through direct, reciprocal actions of STAT3 and STAT5. Nat Immunol 12:247–254
148. Hedrich CM, Rauen T, Apostolidis SA et al (2014) Stat3 promotes IL-10 expression in lupus T cells through trans-activation and chromatin remodeling. Proc Natl Acad Sci U S A 111:13457–13462
149. Chen Z, Lund R, Aittokallio T, Kosonen M, Nevalainen O, Lahesmaa R (2003) Identification of novel IL-4/Stat6-regulated genes in T lymphocytes. J Immunol 171:3627–3635
150. Tuomela S, Rautajoki KJ, Moulder R, Nyman TA, Lahesmaa R (2009) Identification of novel Stat6 regulated proteins in IL-4-treated mouse lymphocytes. Proteomics 9:1087–1098
151. Elo LL, Jarvenpaa H, Tuomela S et al (2010) Genome-wide profiling of interleukin-4 and STAT6 transcription factor regulation of human Th2 cell programming. Immunity 32:852–862
152. Kaplan MH, Schindler U, Smiley ST, Grusby MJ (1996) Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 4:313–319
153. Shimoda K, van Deursen J, Sangster MY et al (1996) Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 380:630–633
154. Takeda K, Tanaka T, Shi W et al (1996) Essential role of Stat6 in IL-4 signalling. Nature 380:627–630
155. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA (2000) Cytokines and systemic lupus erythematosus. Ann Rheum Dis 59:243–251
156. Theofilopoulos AN, Koundouris S, Kono DH, Lawson BR (2001) The role of IFN-gamma in systemic lupus erythematosus: a challenge to the Th1/Th2 paradigm in autoimmunity. Arthritis Res 3:136–141
157. Luzina IG, Knitzer RH, Atamas SP et al (1999) Vasculitis in the Palmerston North mouse model of lupus: phenotype and cytokine production profile of infiltrating cells. Arthritis Rheum 42:561–568
158. Nakajima A, Hirose S, Yagita H, Okumura K (1997) Roles of IL-4 and IL-12 in the development of lupus in NZB/W F1 mice. J Immunol 158:1466–1472
159. Leng RX, Pan HF, Ye DQ, Xu Y (2012) Potential roles of IL-9 in the pathogenesis of systemic lupus erythematosus. Am J Clin Exp Immunol 1:28–32
160. Ouyang H, Shi Y, Liu Z et al (2013) Increased interleukin 9 and CD4+IL-9+ T cells in patients with systemic lupus erythematosus. Mol Med Rep 7:1031–1037
161. Lau M, Tsantikos E, Maxwell MJ, Tarlinton DM, Anderson GP, Hibbs ML (2012) Loss of STAT6 promotes autoimmune disease and atopy on a susceptible genetic background. J Autoimmun 39:388–397
162. Yu HH, Liu PH, Lin YC et al (2010) Interleukin 4 and STAT6 gene polymorphisms are associated with systemic lupus erythematosus in Chinese patients. Lupus 19:1219–1228
163. Krutzik PO, Irish JM, Nolan GP, Perez OD (2004) Analysis of protein phosphorylation and cellular signaling events by flow cytometry: techniques and clinical applications. Clin Immunol 110:206–221
164. Rasmussen TK, Andersen T, Bak RO et al (2015) Overexpression of microRNA-155 increases IL-21 mediated STAT3 signaling and IL-21 production in systemic lupus erythematosus. Arthritis Res Ther 17:154
165. Caprioli F, Sarra M, Caruso R et al (2008) Autocrine regulation of IL-21 production in human T lymphocytes. J Immunol 180:1800–1807
166. Nurieva R, Yang XO, Martinez G et al (2007) Essential autocrine regulation by IL-21 in the generation of inflammatory T cells. Nature 448:480–483
167. Dolff S, Abdulahad WH, Westra J et al (2011) Increase in IL-21 producing T-cells in patients with systemic lupus erythematosus. Arthritis Res Ther 13:157
168. Pratama A, Vinuesa CG (2014) Control of TFH cell numbers: why and how? Immunol Cell Biol 92:40–48
169. Vinuesa CG, Linterman MA, Goodnow CC, Randall KL (2010) T cells and follicular dendritic cells in germinal center B-cell formation and selection. Immunol Rev 237:72–89
170. Ettinger R, Kuchen S, Lipsky PE (2008) The role of IL-21 in regulating B-cell function in health and disease. Immunol Rev 223:60–86
171. Bettelli E, Carrier Y, Gao W et al (2006) Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells. Nature 441:235–238
172. Chaudhry A, Rudra D, Treuting P et al (2009) CD4+ regulatory T cells control TH17 responses in a Stat3-dependent manner. Science 326:986–991
173. Kluger MA, Melderis S, Nosko A et al (2015) Treg17 cells are programmed by Stat3 to suppress Th17 responses in systemic lupus. Kidney Int 89:158–166
174. Yan D, Farache J, Mathis D, Benoist C (2015) Imbalanced signal transduction in regulatory T cells expressing the transcription factor FoxP3. Proc Natl Acad Sci U S A 112:14942–14947
175. Miyara M, Yoshioka Y, Kitoh A et al (2009) Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 30:899–911
176. Sakaguchi S, Miyara M, Costantino CM, Hafler DA (2010) FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol 10:490–500
177. Kalland ME, Oberprieler NG, Vang T, Tasken K, Torgersen KM (2011) T cell-signaling network analysis reveals distinct differences between CD28 and CD2 costimulation responses in various subsets and in the MAPK pathway between resting and activated regulatory T cells. J Immunol 187:5233–5245
178. Moulton VR, Tsokos GC (2015) T cell signaling abnormalities contribute to aberrant immune cell function and autoimmunity. J Clin Invest 125:2220–2227
179. Golding A, Hasni S, Illei G, Shevach EM (2013) The percentage of FoxP3+Helios+ Treg cells correlates positively with disease activity in systemic lupus erythematosus. Arthritis Rheum 65:2898–2906
180. Alexander T, Sattler A, Templin L et al (2013) Foxp3+ Helios+ regulatory T cells are expanded in active systemic lupus erythematosus. Ann Rheum Dis 72:1549–1558
181. Dupont G, Demaret J, Venet F et al (2014) Comparative dose-responses of recombinant human IL-2 and IL-7 on STAT5 phosphorylation in CD4+FOXP3- cells versus regulatory T cells: a whole blood perspective. Cytokine 69:146–149
182. Barron L, Dooms H, Hoyer KK et al (2010) Cutting edge: mechanisms of IL-2-dependent maintenance of functional regulatory T cells. J Immunol 185:6426–6430
183. Horwitz DA (2010) Identity of mysterious CD4+CD25-Foxp3+ cells in SLE. Arthritis Res Ther 12:101
184. Zhang B, Zhang X, Tang FL, Zhu LP, Liu Y, Lipsky PE (2008) Clinical significance of increased CD4+CD25-Foxp3+ T cells in patients with new-onset systemic lupus erythematosus. Ann Rheum Dis 67:1037–1040
185. Bonelli M, Goschl L, Bluml S et al (2014) CD4(+)CD25(-)Foxp3(+) T cells: a marker for lupus nephritis? Arthritis Res Ther 16:104
186. Flores-Borja F, Bosma A, Ng D et al (2013) CD19+CD24hiCD38hi B cells maintain regulatory T cells while limiting TH1 and TH17 differentiation. Sci Transl Med 5:173ra123
187. Blair PA, Norena LY, Flores-Borja F et al (2010) CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic Lupus Erythematosus patients. Immunity 32:129–140